Results 211 to 220 of about 27,203,267 (397)
European Code Against Cancer, 5th edition – hormone replacement therapy, other common medical therapies and cancer
Molecular Oncology, EarlyView.The 5th edition of the European Code Against Cancer (ECAC5) contains 14 recommendations on cancer prevention. Here, we update the cancer prevention recommendations regarding the use of hormone replacement therapy (HRT), which is positioned as recommendation number 13 of the ECAC5.Mangesh A. Thorat, Marc Arbyn, David Baldwin, Xavier Castells, Solveig Hofvind, Urska Ivanus, Carlo Senore, Esther Toes‐Zoutendijk, Carlijn van der Aalst, Carlos Canelo‐Aybar, Fiorella Karina Fernández‐Sáenz, Ariadna Feliu, Hajo Zeeb, Andre L. Carvalho, Erica D'Souza, David Ritchie, Carolina Espina, Iris Lansdorp‐Vogelaar, Andrea DeCensi +18 morewiley +1 more sourceTranscriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication
Molecular Oncology, EarlyView.Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal +16 morewiley +1 more sourceRelationships between heritable dementia risk factors, cardiovascular risk factors in young adulthood, and midlife neuropsychological outcomes. [PDF]
J Alzheimers DisKoychev I, Vaci N, Moonen J, Reid G, Howgego G, Yaffe K, Nasrallah I, Sidney S, Jindra C, Gallacher J, Launer LJ. +10 moreeuropepmc +1 more sourceNext‐generation proteomics improves lung cancer risk prediction
Molecular Oncology, EarlyView.This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner +4 morewiley +1 more sourceGermline variation in the insulin-like growth factor pathway and risk of Barrett’s esophagus and esophageal adenocarcinoma
, 2020 Shruti Dighe, Jianhong Chen, Li Yan, Qianchuan He, Puya Gharahkhani, Lynn Onstad, David Levine, Claire Palles, Weimin Ye, Marilie D. Gammon, Prasad G. Iyer, Lesley Anderson, Geoffrey Liu, Anna H. Wu, James Y. Dai, Wong‐Ho Chow, Harvey A. Risch, Jesper Lagergren, Nicholas J. Shaheen, Leslie Bernstein, Douglas A. Corley, Hans Prenen, John de Caestecker, David MacDonald, Paul Moayyedi, Hugh Barr, Sharon Love, Laura Chegwidden, Stephen E. Attwood, Peter J. Watson, Rebecca Harrison, Katja Ott, Susanne Moebus, Marino Venerito, Hauke Lang, Rupert Mayershofer, Michael Knapp, Lothar Veits, Christian Gerges, Josef Weismüller, Ines Gockel, Yogesh K. Vashist, Markus M. Nöthen, Jakob R. Izbicki, Hendrik Manner, Horst Neuhaus, Thomas Rösch, Anne C. Böhmer, Arnulf H. Hölscher, Mario Anders, Oliver Pech, Brigitte Schumacher, Clemens Schmidt, Thomas Schmidt, Tania Noder, Dietmar Lorenz, Michael Vieth, Andrea May, Timo Hess, Nicole Kreuser, Jessica Becker, Christian Ell, Christine B. Ambrosone, Kirsten B. Moysich, Stuart MacGregor, Ian Tomlinson, David C. Whiteman, Janusz Jankowski, Johannes Schumacher, Thomas L. Vaughan, Margaret M. Madeleine, Laura J. Hardie, Matthew F. Buas +72 moreopenalex +2 more sourcesMonitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer
Molecular Oncology, EarlyView.Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien +35 morewiley +1 more source